India Glycols Limited — PPTs, 06-02-2025: Investor Presentation

**Financial Highlights**: India Glycols Limited (IGL) reported strong financial performance for Q3 and the first nine months of FY25. Q3 FY25 net revenue increased 8% to ₹975 Cr, while gross revenue rose 14% to ₹2,424 Cr. The EBITDA surged 21% to ₹129 Cr, resulting in an improved EBITDA margin of 13.2% compared to 11.8% in Q3 FY24. For 9MFY25, net revenue was up 23% to ₹2,905 Cr, with gross revenue reaching ₹6,850 Cr, marking a 17% increase. PAT for Q3 FY25 increased 37% to ₹57 Cr, with PAT margin improving to 5.8%.

**Strategic Initiatives and Growth Drivers**: The company proposed a restructuring plan to streamline its operations by merging Kashipur Holdings Limited into IGL and demerging distinct business segments into IGL Spirits Limited and Ennature Bio Pharma Limited. This is expected to enhance focus and efficiency in each sector, potentially unlocking value for stakeholders.

**Business Developments**: IGL is continuing to expand its production capacity, particularly in the Bio-Fuel segment, which reported a remarkable 79% revenue growth to ₹272 Cr in Q3 FY25. The introduction of new products within its Potable Spirits segment contributed significantly to overall revenue.

**Market Position and Competitive Advantage**: IGL maintains a solid market position as a leading manufacturer of bio-based specialties, bio-fuels, and potable spirits, benefitting from a sustainable business model and diversified product offerings.

**Investor Implications**: The robust financial growth alongside strategic restructuring strengthens the company’s outlook. Investors should watch for the enhancement in operational efficiency and the potential for increased returns stemming from IGL's focus on sustainability and innovation.